Xeltis Secures Nearly €50M Financing to Enhance Vascular Access Innovations
Xeltis, a pioneering company focused on developing transformative medical implants, has successfully secured nearly €50 million in funding aimed at advancing its innovative product, aXess, into the marketplace. This funding is structured through a significant investment from the European Investment Bank (EIB) and additional support from existing shareholders, including prominent entities such as EQT Life Sciences and Invest-NL.
Investment Breakdown for aXess Development
The financing includes an impressive commitment of up to €37.5 million from the EIB. The investment consists of an upfront amount of €10 million, with the potential to increase by an additional €27.5 million based on future milestones. Alongside this, Xeltis has attracted €10 million from its existing investors, showcasing their continued belief in the company's mission and its pioneering approach in the medtech sector.
Significance of aXess in Hemodialysis Treatment
This investment comes on the heels of encouraging data from Xeltis' pivotal trial, which evaluated aXess's effectiveness as a vascular access conduit for patients with end-stage renal disease. The trial demonstrated impressive results, including sustained patency rates and reduced rates of complications compared to traditional treatment methods. More excitingly, Xeltis anticipates obtaining European market approval and pursuing early market entry in the U.S. by 2026.
Future Vision and Expansion Plans
With these new resources, Xeltis is set on a path not only towards commercialization of aXess but also toward expanding its production capabilities. The company plans to scale its manufacturing processes and hire essential personnel needed to bring its groundbreaking product to market. Eliane Schutte, CEO of Xeltis, expressed gratitude for the backing from the EIB and investors, stating, "This financing empowers us to transform vascular access treatment for hemodialysis patients, a critical area needing innovation."
Backing from EIB and Industry Tsunami
Robert de Groot, Vice President at the EIB, highlighted the importance of supporting innovative companies like Xeltis, which significantly contribute to improving patient outcomes in the healthcare industry. "Xeltis is at the forefront of medical innovation, and our collaboration demonstrates how targeted investments can accelerate advancements in medical technology, enhancing Hungary's leadership in the medtech industry," he stated.
Development of Other Transformative Products
In addition to its efforts to commercialize aXess, Xeltis is also making headway with its broader pipeline of groundbreaking implants. The company utilizes its proprietary Endogenous Tissue Restoration (ETR) platform technology to develop significant medical solutions for patients worldwide. Another promising product under development is Xabg, a coronary artery bypass conduit that has already shown favorable results in clinical trials.
Xeltis aims to address the critical challenges faced by patients requiring cardiovascular replacements and hemodialysis access grafts. Their innovative ETR platform allows for the natural regeneration of the patient’s tissue, offering solutions that traditional approaches cannot match.
Commitment to Innovation and Growth
The financing secured will fuel Xeltis' ambition to make a meaningful impact on healthcare by developing effective and lasting medical solutions. The company is committed to leading the way in creating innovative therapies that empower both patients and healthcare providers. Their forward-thinking approach positions them favorably in the highly competitive medtech landscape, ensuring they continue to rise to significant challenges in healthcare.
Frequently Asked Questions
What is the main purpose of the funding secured by Xeltis?
The funding aims to advance the commercialization of aXess, a vascular access solution for hemodialysis patients, and support broader pipeline development.
Who are the main investors involved in this financing?
The primary investors include the European Investment Bank (EIB) and existing shareholders such as EQT Life Sciences and Invest-NL.
What are the expected outcomes of the aXess clinical trials?
The clinical trials have indicated improved patency rates and safety compared to traditional methods, aiming for both EU market approval and U.S. entry by 2026.
How does Xeltis aim to utilize the new financing?
Xeltis plans to use the financing for production expansion, hiring key personnel, and further developing its innovative pipeline of medical technologies.
What type of technology does Xeltis utilize in its implants?
Xeltis utilizes Endogenous Tissue Restoration (ETR) technology, which enables the natural regeneration of tissues in patients, enhancing long-term outcomes.
